FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer Growth
- 31 May 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 16 (6) , 923-934
Abstract
Breast cancer is a complex and heterogeneous disease, with distinct histologic features dictating the therapy. Although the clinical outcome of breast cancer patients has been considerably improved, the occurrence of resistance to common endocrine and chemotherapy treatments remains the major cause of relapse and mortality. Thus, efforts in identifying new molecules to be employed in breast cancer therapy are needed. As a “faster” alternative to reach this aim, we evaluated whether lamotrigine, a broadly used anticonvulsant, could be “repurposed” as an antitumoral drug in breast cancer. Our data show that lamotrigine inhibits the proliferation, the anchorage-dependent, and independent cell growth in breast cancer cells (BCC), including hormone-resistant cell models. These effects were associated with cell-cycle arrest and modulation of related proteins (cyclin D1, cyclin E, p27Kip1, and p21Waf1/Cip1), all target genes of FoxO3a, an ubiquitous transcription factor negatively regulated by AKT. Lamotrigine also increases the expression of another FoxO3a target, PTEN, which, in turn, downregulates the PI3K/Akt signaling pathway, with consequent dephosphorylation, thus activation, of FoxO3a. Moreover, lamotrigine induces FoxO3a expression by increasing its transcription through FoxO3a recruitment on specific FHRE located on its own promoter, in an autoregulatory fashion. Finally, lamotrigine significantly reduced tumor growth in vivo, increasing FoxO3a expression. Implications: The anticonvulsant drug lamotrigine shows strong antiproliferative activity on breast cancer, both in vitro and in vivo. Thus, drug repurposing could represent a valuable option for a molecularly targeted therapy in breast cancer patients. Mol Cancer Res; 16(6); 923–34. ©2018 AACR.Keywords
All Related Versions
Funding Information
- AIRC (IG 15738/2014)
This publication has 46 references indexed in Scilit:
- PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cellsCell Death & Disease, 2013
- FOXO3 Is a Glucocorticoid Receptor Target and Regulates LKB1 and Its Own Expression Based on Cellular AMP Levels via a Positive Autoregulatory LoopPLOS ONE, 2012
- Therapeutic potential for phenytoin: targeting Nav1.5 sodium channels to reduce migration and invasion in metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Akt, FoxO and regulation of apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Akt2 Inhibition Enables the Forkhead Transcription Factor FoxO3a To Have a Repressive Role in Estrogen Receptor α Transcriptional Activity in Breast Cancer CellsMolecular and Cellular Biology, 2010
- p38α blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1α- to FoxO-dependent transcriptionCell Death & Differentiation, 2009
- Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathyCancer, 2008
- Comparative analysis of the effects of four mood stabilizers in SH‐SY5Y cells and in primary neuronsBipolar Disorders, 2005
- Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7Molecular and Cellular Endocrinology, 2004
- Binding of the Anticonvulsant Drug Lamotrigine and the Neurotoxin Batrachotoxin to Voltage-gated Sodium Channels Induces Conformational Changes Associated with Block and Steady-state ActivationJournal of Biological Chemistry, 2003